TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05262062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strain Counter Strain Technique
Description: When general or local pain began to diminish, upper trapezius , levator scapulae and SCM was placed in a position of ease and was held for approximately 20 to 30 seconds.~2. Moderate digital pressure was applied to the identified MTrP as participants rated their level of pain on a scale ranging from 1 to 10.~3. Ease was defined as the point at which a reduction in pain of at least 70% was achieved.~4. Once the position of ease was identified, it was held for 20 to 30 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique,
Description: After the ease position was maintained for 20 to 30sec an isometric contraction focused on the muscle fibers around the MTrP was performed.~2. Each isometric contraction was held for 7 to 10 sec and was followed by a soft-tissue stretch for 15 seconds and then relax for 30 seconds. Each stretch was held for 30 seconds, and it was repeated 3 times during the treatment session.~3. Treatment was performed on the 3 most painful areas between the upper border of the upper trapezius muscle, the SCM, the levator scapulae, and the SC muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition Technique
Description: 1. Group c will receive Combination of exercise (strain counter strain , muscle energy \& ischemic compression. In ischemic compression patient will receive compression,~2. After MTrPs identification,~3. Ischemic compression was applied in an intermittent manner for up to 2 minutes for each MTrP.~4. The pincer grasp (for the trapezius muscle and SCM) or direct digital pressure (for the levator scapulae and SC muscle) was used with the patients in either the supine position or sitting upright
Study: NCT04858971

Intervention type: OTHER
Intervention: Perception of information source
Description: Participants will see the same health advice, with no source or one of three other sources indicated

Intervention type: OTHER
Intervention: Perception of information source
Description: Participants will see the same health advice, with no source or one of three other sources indicated

Intervention type: OTHER
Intervention: Perception of information source
Description: Participants will see the same health advice, with no source or one of three other sources indicated

Intervention type: OTHER
Intervention: Perception of information source
Description: Participants will see the same health advice, with no source or one of three other sources indicated
Study: NCT05714644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT kit Screening Test
Description: FIT kit mailed to the patient's home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cologuard Screening Test
Description: Cologuard test mailed to the patient's home
Study: NCT05311644

Intervention type: OTHER
Intervention: Telephone survey
Description: All participants are interviewed by telephone, and are asked to answer a survey.
Study: NCT05648669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: 200 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elagolix placebo
Description: Elagolix-matched Placebo tablet
Study: NCT05498480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT05526118

Intervention type: DRUG
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: Patients who are ART-naive adults,18 years of age and older, diagnosed with HIV within 7 days of study entry who have a clinical (diagnosed Opportunistic Infection/AIDS-defining illness) or laboratory (CD4\<200) diagnosis of advanced HIV, who are clinically appropriate for Rapid ART initiation, and are initiated on bic/f/taf per DHHS guidelines at their initial clinic visit will be monitored for time to viral suppression, efficacy and CD4 cell recovery over the course of 48 weeks.
Study: NCT05194839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIST4721
Description: RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIST4721
Description: RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT05363280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL8326 middle dose group
Description: Taken AL3826 at middle dose orally
Study: NCT05832996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refresh Plus Preservative-free Lubricant Eye Drops
Description: Refresh Plus Preservative-free Lubricant Eye Drops at 4 degree Celsius

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Plus Preservative-free Lubricant Eye Drops
Description: Refresh Plus Preservative-free Lubricant Eye Drops at 4 degree Celsius
Study: NCT05537051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM1021, PM8001
Description: Participants will be administered with PM1021 on Part A Day 1. Participants will be administered with PM1021 and PM8001 on Part B Day 1. PM1021 and PM8001 combination therapy administrated every 3 weeks from Part C Day 1 until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion.
Study: NCT04966455

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raisins
Description: Daily supplementation of 50 g of rainsins for 3 months
Study: NCT05363280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL8326 high dose group
Description: Taken AL3826 at high dose orally
Study: NCT06222645

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICG fluorescence imaging technology
Description: Indocyanine green fluorescence imaging uses fluorescence intensity to assess blood perfusion of gastrointestinal anastomoses during gastrointestinal surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICG fluorescence imaging technology
Description: Indocyanine green fluorescence imaging uses fluorescence intensity to assess blood perfusion of gastrointestinal anastomoses during gastrointestinal surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imaging photoplethysmography
Description: Imaging photoplethysmography to assess blood perfusion at gastrointestinal anastomoses during gastrointestinal surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging photoplethysmography
Description: Imaging photoplethysmography to assess blood perfusion at gastrointestinal anastomoses during gastrointestinal surgery
Study: NCT05168904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fadraciclib
Description: Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
Study: NCT05070260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous glenzocimab (ACT017) 1000 mg
Description: Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Description: Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
Study: NCT05564819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The intervention group was given oral acetaminophen, once every 6 hours, for a total of 4 times.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterilized water
Description: When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The control group was given sterilized water, once every 6 hours, for a total of 4 times.
Study: NCT05632770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Collaborative Care
Description: Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: American College of Surgeons (ACS) Required Screening and Referral (Usual Care)
Description: The study will contribute to usual care with the study 10-domain electronic health record (EHR) screen and the posttraumatic stress disorder (PTSD) evaluation. The study team may also collaborate with hospital providers on the referral process and/or inform a member of the patient's care team of distress patients are experiencing as identified by a DSM-5 PTSD Checklist (PCL) score of ≥ 30 or a DSM-IV PTSD Checklist (PCL) score of ≥ 35.
Study: NCT06520163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Day 1\~Day 2: 75mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Day 1\~Day 2: 200g/m\^2, q12h
Study: NCT05140057

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Moviprep
Description: Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Moviprep
Description: Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Moviprep
Description: Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Moviprep
Description: Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
Study: NCT04997239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of quadrivalent influenza vaccine
Description: 15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One dose of quadrivalent influenza vaccine
Description: 15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One dose of quadrivalent influenza vaccine
Description: 15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
Study: NCT05352360

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pilates Exercises
Description: Exercises with Kinesio Taping

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Exercises with Kinesio Taping
Study: NCT00106548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 4mg/kg iv / month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv / month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv / month
Study: NCT06520163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: Day 6: 6mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
Study: NCT00106548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg/week
Study: NCT06520163

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: \[Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) \]± Rituximab (R)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hyper-CVAD
Description: \[Cyclophosphamide + Doxorubicin + Vincristine + Dexamethasone (DXM)\] ± Rituximab
Study: NCT00106548

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 10-25mg/week
Study: NCT06520163

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ID-MTX + Ara-C
Description: \[High-Dose Methotrexate (MTX) + Cytarabine\] ± Rituximab

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: DA-EPOCH
Description: \[Etoposide + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone\] ± Rituximab
Study: NCT05841225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food-related inhibitory control training based on computer
Description: Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are high-calorie and low-calorie food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-food-related inhibitory control training based on computer
Description: Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are non-food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
Study: NCT04642274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Correct the patient's low nutritional status before surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Blood Glucose
Description: Control the patient's blood glucose before surgery, fasting blood glucose level ≤ 8mmol/L or HbA1c ≤ 7%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Take 10% glucose water 6ml/kg 2 to 4 hours before operation (except for diabetes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking and Alcohol
Description: Quit smoking and alcohol before surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Anemia
Description: Correct anemia before surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Transfusion
Description: Use strict blood transfusion indications and blood protection strategy during surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GDFT
Description: Use goal-directed fluid therapy during surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remove the tracheal tube
Description: Remove the tracheal tube as soon as possible after surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating and Drinking
Description: Eat and drink as soon as possible after extubation after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevent Thrombosis
Description: Actively prevent thrombosis after surgery.
Study: NCT06520163

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: GDP
Description: \[Gemcitabine (G) + Cisplatin (P) + Dexamethasone (DXM)\] ± Rituximab

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: GDPE
Description: \[Gemcitabine + Cisplatin + Dexamethasone + Etoposide\] ± Rituximab

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ICE
Description: \[Etoposide + Ifosfamide (IFO) + Carboplatin\] ± Rituximab

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: DICE
Description: \[Dexamethasone + Ifosfamide + Ifosfamide + Etoposide\] ± Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: From Day 6, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
Study: NCT05091242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine injection 3 mcg/kg once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride 0.9 % injection 0.2 mL/kg once
Study: NCT06222944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib: 12mg PO, QD, D1-14, Q3W;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450: 1200 mg, IV, D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 125mg/m2 IV D1,8，Q3W
Study: NCT05497128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrahigh-speed cut rate 27-gauge system
Description: The ultrahigh-speed cut rate 27-gauge system (27+®GA HYPERVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cut rate 27-gauge system
Description: The current standard cut rate 27-gauge vitrectomy system (27+®GA Advanced ULTRAVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
Study: NCT05414760

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Womed Leaf
Description: Womed Leaf™ is a sterile, degradable film of poly(D,L-lactide) (PLA) and poly(ethylene oxide) (PEO). PEO is a biocompatible polymer with anti-adhesion and swelling properties. It is polymerized with hydrophobic PLA to form a degradable film. Womed Leaf™ is inserted in the uterine cavity by a gynaecologist surgeon with a 5 mm diameter flexible inserter. Once released, the film unfolds and grows into the uterine cavity to create a mechanical barrier and keep the uterine walls separated for approximately one week. It is then degraded and discharged naturally through the cervix.
Study: NCT06189274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anatomy-Based Electrode Array Selection
Description: Use of pre-operative imaging to select the appropriate length electrode vs standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Electrode Array Selection
Description: Use of standard of care electrode which is the FLEX 28 electrode
Study: NCT06197529

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Homeostatic Plasticity
Description: Anodal tDCS S1/M1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Homeostatic Plasticity
Description: Anodal tDCS S1/M1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeostatic Plasticity
Description: Anodal tDCS S1/M1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical alone (Capsaicin 8% Patch)
Description: 4x4 patch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: 4x4 patch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: 4x4 patch

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Patch
Description: 4x4 patch

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Homeostatic Plasticity (Sham)
Description: sham Homeostatic Plasticity protocol over S1
Study: NCT05624541

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements
Description: All infants at high risk of cp will be assessed by Specific Test of Early Infant Motor Performance (STEP) Version 3.0 at term age and at corrected age 3 months, by Hammersmith Infant Neurological Examination (HINE) a corrected age 3 and 6 months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at corrected 6 months.
Study: NCT06325501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200mcg Tab
Description: receiving a preoperative rectal dose of 800 ug of misoprostol half an hour before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: after the induction of general anaesthesia (GA), an infusion of 40 IU oxytocin in 500 ml normal saline was started at the rate of 250 ml/hour
Study: NCT06538766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training with an internal focus of attention
Description: A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific internal focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training with a proprioceptive external focus of attention
Description: A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific proprioceptive external focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training with a visual external focus of attention
Description: A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific visual external focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
Study: NCT05322213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: 2-Week, once daily, flexible dose, inhaled THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC
Description: 2-Week, once daily, flexible dose, inhaled THC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2-Week, once daily, flexible dose, inhaled placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2-Week, once daily, flexible dose, inhaled placebo